We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
신규 편입 · 포트폴리오 비중 0.01%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $45.88 · 8 analysts
Stored first · Google News · Yahoo Finance (English)
Castle Biosciences CEO Maetzold sells $95,622 in company stock - Investing.com
Castle Biosciences CEO Maetzold sells $95,622 in company stock Investing.com
Form 4 Castle Biosciences Inc For: 16 July By Investing.com - Investing.com Canada
Form 4 Castle Biosciences Inc For: 16 July By Investing.com Investing.com Canada
Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts - Stock Titan
Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts Stock Titan
New York State Approves Castle Biosciences’ Gene Expression Test to Guide Atopic Dermatitis Treatment - Clinical Lab Products
New York State Approves Castle Biosciences’ Gene Expression Test to Guide Atopic Dermatitis Treatment Clinical Lab Products
Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com - Investing.com Nigeria
Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com Investing.com Nigeria
Castle Biosciences Gets New York State Department of Health Approval of AdvanceAD-Tx Test
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 03. | After market close (AMC) | $-0.4 | — | — | $86.26M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.9 | — | — | $87.99M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.3 | — | — | $245.76M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $0.22 | — | — | $159.98M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 13. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 05. 07. | Baird | — | Maintain | Outperform → Outperform | — | Baird: Outperform |
| 2026. 04. 21. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 02. 27. | Baird | — | Maintain | Outperform → Outperform | — | Baird: Outperform |
| 2026. 01. 27. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
| 2026. 01. 13. | Lake Street | — | Maintain | Buy → Buy | — | Lake Street: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 248,840 | $6.11M | 0.01% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 119,458 | $4.65M | 0.01% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 84,066 | $3.27M | 0.01% | — | New position |